跳至主要内容
临床试验/NCT03451526
NCT03451526已完成不适用

A Multi-centre Real-world Non-interventional Observational Study to Compare Prognoses of the Chinese Patients With N2 Non-small Cell Lung Cancer Who Received Adjuvant Chemotherapies and Perioperative Chemotherapies After Surgeries

Tang-Du Hospital10 个研究点 分布在 1 个国家目标入组 2,929 人开始时间: 2017年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
2,929
试验地点
10
主要终点
Overall survival

研究概览

简要总结

The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cancer

详细描述

The trial is a multi-centre real-world non-interventional observational study. The Chinese patients with N2 non-small cell lung cancer enrolled from 2014 to 2017 who received radical resections of lung cancer and adjuvant chemotherapies will be included in the study and the study data on patient demographic/tumor biological characteristics and clinical treatment will be collected to evaluate compare effectiveness of radical resection of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies after surgeries.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with radical resection of lung cancer enrolled from 2014 to 2019;
  • Pathologically diagnosed patients with non-small cell lung cancer;
  • Patients with age > 18 years old;
  • Patients who did not receive chest surgeries before hospitalization;
  • Patients with N2 lymph nodes (+) after surgeries;
  • Patients who received lymphadenectomy for one group or more groups of lymph nodes;

排除标准

  • Patients with second primary tumors or multiple primary tumors;

结局指标

主要结局

Overall survival

时间窗: 2014 - 2017

Overall survival

次要结局

  • Disease-free survival(2014 - 2017)

研究者

发起方
Tang-Du Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

lixiaofei

Professor

Tang-Du Hospital

研究点 (10)

Loading locations...

相似试验